Spirogen in antibody drug conjugate alliance with Genentech
This article was originally published in Scrip
Executive Summary
Spirogen, an oncology-focused company developing DNA sequence targeted agents, has entered a multi-year research collaboration and licence agreement with Genentech (Roche).